Flexible content designed to fit a range of applications and plex needs
The GeoMx RNA and Protein assays allow you to profile up to 96 RNA or protein targets from a single FFPE slide with Digital Spatial Profiling. GeoMx Assays are pre-validated and modular to provide flexibility and support a range of research needs. For protein, select one 20-plex core and up to six 10-plex modules to analyze expression of your proteins of interest. Additionally, antibodies can be customized for use with GeoMx DSP through the Protein Barcoding Service. For RNA, select a core panel with the option to add custom user defined-content.
Available content covers immunology, immuno-oncology, neurodegeneration, and neuroinflammation with a rapidly growing pipeline.
|Cores||Immune Cell Profiling
|Neuro Cell Profiling
|Modules||IO Drug Target (6-10-plex, H/M)
Immune Activation Status (8-plex, H)
Immune Cell Typing (7-plex, H)
Pan-Tumor (9-plex, H)
H = Human; H/M = Human/Mouse
All GeoMx Protein Assays undergo extensive validation to ensure high quality GeoMx DSP data.
1) First antibodies undergo an incoming immunohistochemistry (IHC) screen in control tissue to confirm off-the-shelf performance.
2) Next, antibodies are conjugated to indexing oligonucleotides and IHC testing is performed to confirm post-conjugation specificity.
3) After the post-conjugation screen, antibodies are assessed for sensitivity and specificity using control FFPE cell pellets.
4) The next step after confirming performance of antibodies in single plex is to perform an interaction screen to ensure high performance in the multiplex mix.
5) Finally, the antibody mix is subjected to a tissue microarray (TMA) screen using normal and relevant disease tissue to confirm the performance of the targets included in the final assay. See our product bulletins for more information.
Download the GeoMx Antibody Validation White Paper for more information
All GeoMx RNA Assays undergo extensive validation to ensure high quality GeoMx DSP data.
1) First probe sequences are screened for specificity and cross hybridization.
2) Next, probes are assessed for sensitivity and specificity using control FFPE cell pellets.
3) Probes are then pooled and tested to ensure equimolar concentrations.
4) Finally, the probe mix is subjected to a tissue microarray (TMA) screen using normal and relevant disease tissue to confirm the performance of the targets included in the final assay.
For Research Use Only. Not for use in diagnostic procedures.